Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview
- PMID: 18991752
- DOI: 10.2174/138955708786369546
Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview
Abstract
Type 2 diabetes is a major health problem associated with excess mortality and morbidity. Vascular complications are one of the most serious consequences of this disorder. Moreover, type 2 diabetes is also a risk factor for cerebral complications, including cognitive impairment and dementia. However, it has been shown that tight glycemic control contributes to reduce the incidence of diabetes-associated complications. Metformin is a potent antihyperglycemic agent widely used in the management of type 2 diabetes whose main actions are the suppression of gluconeogenesis and the improvement of glucose uptake and insulin sensitivity. This review is mainly devoted to describe the mechanisms of action underlying the antidiabetic effects of metformin. Furthermore, we will present evidence for the protective effects of metformin against diabetes-associated complications mainly cerebral and vascular complications. Finally, we will describe the few known side effects associated to this antidiabetic agent.
Similar articles
-
Metformin: an update.Ann Intern Med. 2002 Jul 2;137(1):25-33. doi: 10.7326/0003-4819-137-1-200207020-00009. Ann Intern Med. 2002. PMID: 12093242 Review.
-
Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.J Fam Pract. 1996 Jun;42(6):612-8. J Fam Pract. 1996. PMID: 8656173 Review.
-
Improved endothelial function with metformin in type 2 diabetes mellitus.J Am Coll Cardiol. 2001 Apr;37(5):1344-50. doi: 10.1016/s0735-1097(01)01129-9. J Am Coll Cardiol. 2001. PMID: 11300445 Clinical Trial.
-
Metformin: diamonds are forever.Expert Opin Pharmacother. 2009 Oct;10(15):2395-7. doi: 10.1517/14656560903176453. Expert Opin Pharmacother. 2009. PMID: 19678795
-
A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.Curr Med Res Opin. 2006;22 Suppl 2:S39-48. doi: 10.1185/030079906X121002. Curr Med Res Opin. 2006. PMID: 16914074 Review.
Cited by
-
Metformin Down-regulates TNF-α Secretion via Suppression of Scavenger Receptors in Macrophages.Immune Netw. 2013 Aug;13(4):123-32. doi: 10.4110/in.2013.13.4.123. Epub 2013 Aug 26. Immune Netw. 2013. PMID: 24009539 Free PMC article.
-
Impact of metformin use on the prognostic value of lactate in sepsis.Am J Emerg Med. 2012 Nov;30(9):1667-73. doi: 10.1016/j.ajem.2012.01.014. Epub 2012 Mar 16. Am J Emerg Med. 2012. PMID: 22424991 Free PMC article.
-
In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.BMC Cancer. 2012 Nov 14;12:517. doi: 10.1186/1471-2407-12-517. BMC Cancer. 2012. PMID: 23151022 Free PMC article.
-
Metformin Reduces Lipogenesis Markers in Obese Mice Fed a Low-Carbohydrate and High-Fat Diet.Lipids. 2016 Dec;51(12):1375-1384. doi: 10.1007/s11745-016-4209-y. Epub 2016 Nov 1. Lipids. 2016. PMID: 27804063
-
Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways.J Exp Clin Cancer Res. 2015 Aug 7;34(1):77. doi: 10.1186/s13046-015-0183-0. J Exp Clin Cancer Res. 2015. PMID: 26245871 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical